CM Management LLC Has $1.07 Million Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

CM Management LLC raised its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 40.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 700,000 shares of the biotechnology company’s stock after purchasing an additional 200,000 shares during the quarter. CM Management LLC owned approximately 0.46% of Heron Therapeutics worth $1,071,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in HRTX. Y Intercept Hong Kong Ltd acquired a new stake in shares of Heron Therapeutics during the third quarter worth $39,000. Capstone Investment Advisors LLC acquired a new stake in Heron Therapeutics during the 3rd quarter worth about $45,000. King Wealth Management Group raised its position in shares of Heron Therapeutics by 52.3% in the 3rd quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 8,000 shares in the last quarter. Glenmede Trust Co. NA lifted its stake in shares of Heron Therapeutics by 49.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 10,578 shares during the period. Finally, Cutter & CO Brokerage Inc. boosted its position in shares of Heron Therapeutics by 69.6% during the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 13,600 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on HRTX. Needham & Company LLC reissued a “buy” rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Friday, February 28th. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday.

Heron Therapeutics Stock Performance

Shares of NASDAQ:HRTX opened at $2.39 on Friday. The firm has a market cap of $364.07 million, a P/E ratio of -13.28 and a beta of 1.55. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.93. The business’s 50 day simple moving average is $1.77 and its two-hundred day simple moving average is $1.73.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.05. The business had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. On average, equities analysts forecast that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.